ReviewDrugs2012
Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.
Review in Drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 75 citations in OpenAlex.
- Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Trial
- Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.Addiction science & clinical practice · 2022Trial
- Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all-cause mortality among people with opioid use disorder: A retrospective population-based target trial emulation study in British Columbia, Canada, 2010-2020.Addiction (Abingdon, England) · 2026Observational
- AT1R in Central Nervous System Disorders: Unveiling Novel Mechanisms and Therapeutic Avenues for Addiction.Addiction biology · 2026Review
- Travel Time to Methadone Treatment Via Personal Vehicle vs Public Transit.JAMA network open · 2026Article
- Interest in HIV pre-exposure prophylaxis use and associated factors among people who inject drugs in Iran: a nationwide survey in 2023.Scientific reports · 2026Article
- Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: A retrospective cohort study.Drug and alcohol dependence · 2025Article
- The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model.Neuropharmacology · 2024Article
- Article
- Tabernanthalog Reduces Motivation for Heroin and Alcohol in a Polydrug Use Model.Psychedelic medicine (New Rochelle, N.Y.) · 2023Article
- Methods for jurisdictional vulnerability assessment of opioid-related outcomes.Preventive medicine · 2023Article
- Review
- Synergistic immune and antinociceptive effects induced from the combination of two different vaccines against morphine/heroin in mouse.Human vaccines & immunotherapeutics · 2021Article
- Article
- Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study.BMJ (Clinical research ed.) · 2020Article
- Potential uses of naltrexone in emergency department patients with opioid use disorder.Clinical toxicology (Philadelphia, Pa.) · 2019Review
- Alcohol and Drug Abuse Resource Utilization in the ICU.Substance abuse : research and treatment · 2019Article
- Management of Substance Use Disorder in Military Services: A Comprehensive Approach.Advanced biomedical research · 2017Article
- Article
- Caring for patients with opioid use disorder in the hospital.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and indirectly through criminal activity, absenteeism and lost productivity. Opioid agonist medications, such as methadone and buprenorphine, that stabilize neuronal systems and provide narcotic blockade are the most effective treatments. Prolonged provision of these medications, defined as maintenance treatment, typically produces improved outcomes when compared with short-duration tapers and withdrawal. The benefits of opioid agonist maintenance include decreased illicit drug use, improved retention in treatment, decreased HIV risk behaviours and decreased criminal behaviour. While regulations vary by country, these medications are becoming increasingly available internationally, especially in regions experiencing rapid transmission of HIV due to injection drug use. In this review, we describe the rationale for maintenance treatment of opioid dependence, discuss emerging uses of opioid antagonists such as naltrexone and sustained-release formulations of naltrexone and buprenorphine, and provide a description of the experimental therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.